BioCentury
ARTICLE | Company News

Bristol-Myers infectious news

June 29, 2015 7:00 AM UTC

Bristol-Myers said it will discontinue drug discovery in virology and cut about 100 jobs as part of an ongoing R&D reorganization announced in 2013. The company said the change will not affect its clinical-stage and marketed virology products. BMS’s marketed virology products include cyclopentyl guanosine nucleoside analog Baraclude entecavir to treat HBV infection; HIV protease inhibitor Reyataz atazanavir; and selective HCV NS5A protein inhibitor Daklinza daclatasvir and HCV NS3 protease inhibitor Sunvepra asunaprevir to treat HCV infection. Its pipeline products include BMS-663068, an HIV-1 attachment inhibitor that binds directly to HIV-1 gp120 that is in Phase III testing to treat HIV-1 infection; second-generation HIV-1 maturation inhibitor BMS-955176, which is in Phase II testing to treat HIV-1 infection; and non-nucleoside HCV NS5B polymerase inhibitor beclabuvir ( BMS-791325), which is in Phase II testing to treat HCV infection (see BioCentury, Nov. 11, 2013). ...